Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Human Mutation

• Publication date

  2001-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/humu.1167PMID 11462242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of a founder BRCA2 mutation in Sardinia

  2000cited by this paper
• BRCA1 and BRCA2 genes: Role in hereditary breast and ovarian cancer in Italy

  1999cited by this paper
• A new L771L polymorphism in the BRCA1 gene frequently found in southern Italy

  1999cited by this paper
• Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.

  1999cited by this paper
• Laboratory identification of hereditary risk of breast and ovarian cancer.

  1999cited by this paper
• Ethnic differences in cancer risk resulting from genetic variation

  1999cited by this paper
• Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study.

  1998cited by this paper
• Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.

  1998cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Population genetics of BRCA1 and BRCA2.

  1997cited by this paper
• High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.

  1996cited by this paper
• Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study.

  1996cited by this paper
• BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations.

  1996cited by this paper
• Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1995cited by this paper
• Germline mutation of BRCA1 in Japanese breast cancer families.

  1995cited by this paper
• The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

  1995cited by this paper
• The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium.

  1994cited by this paper
• Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer

  1994cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

  1994cited by this paper
• The genetic epidemiology of BRCA1

  1994cited by this paper
• Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

  1989cited by this paper

• Cascade Genetic Testing for Hereditary Cancer Predisposition: Characterization of Patients in a Catchment Area of Southern Italy

  2025influential citation
• Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing

  2024cites this paper
• The BRCA1 c.4096+1G>A Is a Founder Variant Which Originated in Ancient Times

  2023cites this paper
• Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy

  2022cites this paper
• Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?

  2022cites this paper
• Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).

  2021cites this paper
• Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa

  2021cites this paper
• Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy

  2021influential citation
• Spectrum of Germline BRCA1 and BRCA2 Variants Identified in 2351 Ovarian and Breast Cancer Patients Referring to a Reference Cancer Hospital of Rome

  2020influential citation
• The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

  2018cites this paper
• Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant

  2018cites this paper
• BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far.

  2018cites this paper
• High Resolution Melting Analysis is Very Useful to Identify Breast Cancer Type 1 Susceptibility Protein (BRCA1) c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA

  2017cites this paper
• The Influence of Estradiol and HDL-Cholesterol levels on Breast Cancer in Pre-menopause and Menopause Women and its Correlation with BRCA1 Gene C61G Mutation

  2017cites this paper
• Identification of twenty-nine novel germline unclassified variants of BRCA1 and BRCA2 genes in 1400 Italian individuals.

  2017cites this paper
• Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

  2016cites this paper
• Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy

  2016cites this paper
• Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional Implications

  2015cites this paper
• Clinical interpretation and implications of whole-genome sequencing.

  2014cites this paper
• BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries

  2013cites this paper
• Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

  2013cites this paper
• A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?

  2013cites this paper
• Identification of low-penetrance alleles, genetic modifiers and mutation analysis in familial breast cancer cases

  2013cites this paper
• Identification and Characterization of BRCA 1 and BRCA 2 Founder Mutations

  2012cites this paper
• Breast Cancer Gene 1 ( Brca 1 ) Mutation In Female Patients With Or Without Family History In Qalubia Governorate

  2011influential citation
• HER2-positive male breast cancer: an update.

  2010cites this paper
• Founder BRCA 1 / 2 mutations in the Europe : implications for hereditary breast-ovarian cancer prevention and control

  2010influential citation
• Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control

  2010influential citation
• Male breast cancer.

  2010cites this paper
• Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics

  2010cites this paper
• Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy

  2009cites this paper
• BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy

  2009cites this paper
• The Genetics of Breast Cancer

  2009cites this paper
• Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis

  2008cites this paper
• Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families

  2008cites this paper
• Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?

  2008cites this paper
• BRCA 15083 del 19 Mutant Allele Selectively UpRegulates Periostin Expression In vitro and In vivo

  2008cites this paper
• BRCA1 5083del19 Mutant Allele Selectively Up-Regulates Periostin Expression In vitro and In vivo

  2008cites this paper
• Immunoregulation by Mycobacterium vaccae : effects on CD11c+ antigen-presenting cells in a mouse model of pulmonary inflammation.

  2007cites this paper
• Identification of a founder BRCA2 mutation in Sardinian breast cancer families

  2007cites this paper
• Founder mutations in BRCA1 and BRCA2 genes.

  2007cites this paper
• BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses

  2007cites this paper
• 4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily).

  2007cites this paper
• BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.

  2007cites this paper
• Sharing mass spectrometry data in a grid-based distributed proteomics laboratory

  2007cites this paper
• Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.

  2006cites this paper
• Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families

  2006cites this paper
• High-throughput experimental verification of predicted tissue-specific and tumor-specific splice isoforms

  2005cites this paper
• BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.

  2005cites this paper
• An Architecture for Managing Mass Spectrometry Data for a Distributed Proteomics Laboratory

  2005cites this paper
• Preprocessing of mass spectrometry proteomics data on the grid

  2005cites this paper
• ERβ in normal and malignant breast

  2005cites this paper
• The allele (A)-110 in the promoter region of the HSP70-1 gene is unfavorable to longevity in women

  2004cites this paper
• The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use

  2004cites this paper
• Genetic alterations in hereditary breast cancer.

  2004cites this paper
• A novel Q3034R BRCA2 germline mutation identified in a fallopian tube cancer patient.

  2003cites this paper
• Proteomic Profiling of Inherited Breast Cancer: Identification of Molecular Targets for Early Detection, Prognosis and Treatment, and Related Bioinformatics Tools

  2003cites this paper
• BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer

  2003cites this paper
• BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.

  2003cites this paper
• Study in Italy Characteristics in Male Breast Cancer : A Population-based Mutation Status and Tumor BRCA 2 and BRCA 1 Updated Version

  2003cites this paper
• BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy

  2003cites this paper
• BRCA 1 and BRCA 2 Mutation Status and Tumor Characteristics in Male Breast Cancer : A Population-based Study in Italy 1

  2003cites this paper
• BRCA mutations in Italian breast/ovarian cancer families

  2002cites this paper
• Polymorphisms in DNA repair and environmental interactions.

  2002cites this paper
• Polymorphisms in DNA repair and environmental interactions.

  2002cites this paper
• The Application of Clinical Genetics Dovepress Inherited and Acquired Alterations in Development of Breast Cancer

  year unknowncites this paper